Armour Thyroid (Desiccated Thyroid Extract) - Comprehensive Research Paper

Document Information

• Product Name: Armour Thyroid (Thyroid Tablets, USP)
• Brand Name(s): Armour Thyroid (primary), NP Thyroid, Nature-Throid, WP Thyroid, generic DTE
• Category: Desiccated Thyroid Extract (DTE) / Natural Desiccated Thyroid (NDT)
• Paper Number: 47 of 76
• Last Updated: 2025-12-26

Table of Contents

1. Summary
2. Mechanism of Action
3. FDA-Approved Indications
4. Dosing and Administration
5. Pharmacokinetics
6. Side Effects and Adverse Reactions
7. Drug Interactions
8. Contraindications
9. Special Populations
10. Monitoring Parameters
11. Cost and Availability
12. Clinical Evidence Summary
13. Comparison with Alternatives
14. Storage and Handling
15. Goal Archetype Integration
16. Age-Stratified Dosing
17. Drug Interactions (Comprehensive)
18. Bloodwork Impact
19. Protocol Integration
20. References

Goal Relevance:

• Improve energy levels and reduce fatigue associated with hypothyroidism
• Support weight management and metabolism for those with thyroid issues
• Enhance mental clarity and reduce brain fog linked to thyroid hormone imbalances
• Optimize hormone levels for better overall well-being in thyroid patients
• Address symptoms of low thyroid function such as cold intolerance and dry skin
• Provide an alternative thyroid treatment for patients with impaired T4 to T3 conversion

1. Summary

Overview

Armour Thyroid is a desiccated thyroid extract (DTE) derived from porcine (pig) thyroid glands that has been used to treat hypothyroidism for over a century. Unlike synthetic thyroid preparations, Armour Thyroid contains the complete spectrum of thyroid hormones found in mammalian thyroid tissue, including both thyroxine (T4) and triiodothyronine (T3), along with smaller amounts of diiodothyronine (T2), monoiodothyronine (T1), and thyroglobulin.

Historical Significance

Desiccated thyroid extract represents the original form of thyroid hormone replacement therapy:

Timeline:

• 1891: George Murray first used thyroid extract for myxedema treatment
• 1914: Armour and Company standardized thyroid tablets
• 1950s-1960s: Synthetic levothyroxine (T4) introduced
• 1970s-present: Synthetic T4 becomes dominant treatment
• 2002: Levothyroxine gains FDA approval
• 2020s: FDA regulatory action on unapproved DTE products

Regulatory Status (Critical 2025 Update)

FDA STATUS: NOT APPROVED

Armour Thyroid and all desiccated thyroid products have never been FDA-approved. They have been marketed under historical "grandfathering" provisions:

August 2025 FDA Action:

• FDA sent letters to all DTE manufacturers stating intent to take regulatory action
• DTE products classified as biological products under Public Health Service Act
• Manufacturers notified they must obtain Biologics License Application (BLA) approval
• Transition period granted to allow patients to switch to approved alternatives
• AbbVie reportedly preparing preliminary steps for BLA submission

Current Market Status

• Approximately 1.5 million patients in the US receive DTE (6% of thyroid patients)
• 94% of thyroid patients (24 million) receive FDA-approved synthetic levothyroxine
• Future availability uncertain pending BLA approval

Key Composition

Per Grain (60 mg) of Armour Thyroid:

• Levothyroxine (T4): 38 mcg
• Liothyronine (T3): 9 mcg
• T4:T3 ratio: Approximately 4:1

Comparison to Human Physiology:

• Human thyroid produces T4:T3 at approximately 14:1 ratio
• DTE provides relatively more T3 than natural human production
• T3 is approximately 4x more potent than T4 per microgram

Clinical Positioning

Potential Advantages:

• Contains both T4 and T3 hormones
• Some patients report improved well-being vs T4 alone
• May benefit patients with impaired T4 to T3 conversion
• Historical track record of clinical use

Significant Concerns:

• Not FDA approved
• Inconsistent T4/T3 ratios between batches
• Higher T3 exposure than physiologic
• Cardiac risks (atrial fibrillation)
• Bone density concerns
• Uncertain future availability

2. Mechanism of Action

Thyroid Hormone Physiology

Normal Thyroid Hormone Production

The thyroid gland produces and releases thyroid hormones in response to thyroid-stimulating hormone (TSH) from the pituitary:

Hormone Production:

• T4 (thyroxine): Approximately 80-90 mcg/day
• T3 (triiodothyronine): Approximately 5-10 mcg/day
• Physiologic T4:T3 ratio: Approximately 14:1

Peripheral Conversion:

• Most circulating T3 comes from peripheral conversion of T4
• Deiodinase enzymes (D1, D2, D3) regulate conversion
• Liver, kidney, muscle are major conversion sites
• Some patients may have impaired conversion

Mechanism of Desiccated Thyroid Extract

Composition and Activity

Armour Thyroid provides thyroid hormones identical to those produced by the human thyroid:

Active Components:

Thyroid Hormone Receptor Action

Both T4 and T3 exert effects through nuclear thyroid hormone receptors:

Receptor Binding:

• T3 binds with ~10-15 fold higher affinity than T4
• T3 is the primary active hormone at the receptor level
• Receptor binding initiates gene transcription

Target Tissues:

• Heart: Increases rate and contractility
• Metabolism: Increases basal metabolic rate
• Brain: Development and cognitive function
• Bone: Affects remodeling and turnover
• Liver: Protein synthesis, cholesterol metabolism
• Muscle: Protein synthesis, metabolism

Comparative Hormone Activity

T4 (Levothyroxine):

• Functions primarily as prohormone
• Long half-life (~7 days) provides stable levels
• Converted to T3 in peripheral tissues
• Less immediate metabolic activity

T3 (Liothyronine):

• Directly active at thyroid receptors
• Short half-life (~24 hours)
• Rapid onset of action
• More potent metabolic effects
• Approximately 4x more potent than T4 per mcg

Unique Aspects of DTE

Natural vs Synthetic Hormones

Chemically Identical:

• T4 in Armour Thyroid is chemically identical to synthetic levothyroxine
• T3 in Armour Thyroid is chemically identical to synthetic liothyronine
• Both are the L-isomer (natural form)

Potential Differences:

• Bioavailability may differ slightly
• Absorption characteristics may vary
• Presence of other thyroid constituents (T2, T1, thyroglobulin)

Non-T4/T3 Components

Thyroglobulin:

• Large protein that stores thyroid hormones
• FDA basis for classifying DTE as biologic
• No established therapeutic role
• May contribute to allergic reactions

Minor Iodothyronines (T2, T1):

• Present in small amounts
• Emerging research on metabolic effects
• Clinical significance unclear

Feedback Loop Effects

Pituitary-Thyroid Axis

Normal Feedback:

• Low thyroid hormones → increased TSH
• High thyroid hormones → suppressed TSH
• DTE affects this loop similarly to synthetic hormones

T3 Effect on TSH:

• Exogenous T3 rapidly suppresses TSH
• May result in lower TSH than with T4 alone
• Some practitioners target higher TSH to avoid overtreatment

Tissue-Specific Effects

Heart

Direct T3 Effects:

• Increased heart rate (chronotropy)
• Increased contractility (inotropy)
• Shortened refractory period (proarrhythmic)
• Risk of atrial fibrillation with excess T3

Bone

Thyroid Hormone Effects:

• Accelerates bone turnover
• Excess causes net bone loss
• Risk of osteoporosis with overtreatment
• Greater concern with T3 than T4

Brain and Mood

Central Effects:

• Affects neurotransmitter systems
• Influences mood and cognition
• Some patients report improved well-being on DTE
• Mechanism of preferential response unclear

3. FDA-Approved Indications

CRITICAL: Not FDA Approved

Armour Thyroid and all desiccated thyroid products are NOT FDA approved

Historical Marketing Status

DTE products have been marketed in the US for over 100 years under historical precedent rather than FDA approval:

Pre-1938 Status:

• DTE products existed before the Federal Food, Drug, and Cosmetic Act
• Were considered "grandfathered" under certain interpretations
• Never subjected to modern FDA approval process

Current Reality:

• FDA has not formally approved any DTE product
• Products marketed under industry interpretation of regulations
• FDA now taking action to address this regulatory gap

August 2025 FDA Regulatory Action

FDA Letters to Manufacturers

On August 6, 2025, FDA sent formal notices to DTE manufacturers:

Key Points:

1. Animal-derived thyroid medications are not FDA approved
2. Products are classified as biological products under the Public Health Service Act
3. Biologics License Application (BLA) required for continued marketing
4. Not eligible for compounding as biological products
5. FDA not taking immediate action to allow patient transition time

Implications

For Patients:

• Products may eventually be removed from market
• Transition to FDA-approved alternatives may be necessary
• Uncertain timeline for any changes

For Manufacturers:

• Must pursue BLA approval or discontinue production
• BLA process typically takes several years to a decade
• AbbVie reportedly preparing for BLA submission for Armour Thyroid

Labeled Indications (Unapproved)

Current Package Insert Indications

The product labeling lists the following indications, though not FDA approved:

1. Hypothyroidism:

• Primary (thyroid failure)
• Secondary (pituitary)
• Tertiary (hypothalamic)

2. Thyroid Suppression Therapy:

• Pituitary TSH suppression
• Thyroid gland suppression for diagnostic purposes

3. Adjunctive Therapy:

• Thyroid cancer management (in conjunction with other treatments)
• Thyroiditis

Comparison to FDA-Approved Alternatives

Clinical Use Considerations

When DTE is Considered

Despite lack of FDA approval, clinicians may prescribe DTE for:

1. Persistent Symptoms on Levothyroxine:

   • Some patients remain symptomatic despite normal TSH
   • May benefit from added T3 component

2. Patient Preference:

   • Desire for "natural" product
   • Historical use and familiarity

3. Impaired T4 to T3 Conversion:

   • Patients with suspected conversion defects
   • DIO2 gene polymorphisms

Medical Society Positions

American Thyroid Association:

• Recommends levothyroxine as treatment of choice
• Does not recommend routine use of DTE
• Notes lack of evidence for superiority

American Association of Clinical Endocrinologists:

• Similar position favoring synthetic levothyroxine
• Recommends against DTE for first-line therapy

4. Dosing and Administration

Dosage Forms

Armour Thyroid Available Strengths

Initial Dosing

Standard Initiation

Healthy Adults:

• Starting dose: 30 mg (1/2 grain) once daily
• Increase by 15 mg every 2-4 weeks as tolerated
• Titrate based on clinical response and laboratory values

Elderly or Cardiac Patients:

• Starting dose: 15 mg (1/4 grain) once daily
• Very gradual titration over months
• Lower target doses may be appropriate

Patients with Severe Hypothyroidism:

• Start very low: 15 mg (1/4 grain)
• Slow titration essential to avoid cardiac stress
• Particularly cautious in myxedema

Maintenance Dosing

Typical Maintenance Range

Adults:

• Most patients: 60-120 mg (1-2 grains) daily
• Some require higher doses up to 180-300 mg
• Individualized based on response and labs

Dose Optimization:

• Monitor TSH, free T4, and free T3
• Clinical symptoms important in addition to labs
• Some practitioners also check T3:T4 ratio

Dose Conversion Charts

Levothyroxine to Armour Thyroid

Important Notes:

• Conversions are approximate guides only
• Clinical judgment supersedes conversion tables
• May need adjustment based on individual response
• T3 content means 1:1 mcg conversion doesn't apply

Administration Guidelines

Timing

Standard Recommendation:

• Take in the morning on empty stomach
• 30-60 minutes before breakfast
• Alternatively, at bedtime (4+ hours after eating)

Food Effects:

• Food decreases absorption
• High-fiber foods particularly affect absorption
• Calcium, iron supplements affect absorption

Divided Dosing

Rationale:

• T3 component has short half-life (~24 hours)
• Some practitioners divide dose for more stable T3 levels
• Example: 60 mg split as 30 mg AM and 30 mg afternoon

Considerations:

• More complicated regimen
• May improve T3 stability
• No definitive evidence of superiority

Special Dosing Situations

Switching from Levothyroxine

Approach:

1. Calculate equivalent DTE dose from conversion table
2. May start slightly lower (75% of calculated dose)
3. Monitor closely during transition
4. Adjust based on symptoms and labs after 4-6 weeks

Switching to Levothyroxine

If DTE becomes unavailable:

1. Calculate equivalent levothyroxine dose
2. Consider adding liothyronine for patients who need T3
3. Monitor TSH after 6-8 weeks
4. Adjust as needed

Dose Adjustments

Situations Requiring Dose Changes

Increased Requirements:

• Pregnancy (significant increase needed)
• Weight gain
• Malabsorption conditions
• Certain medications (see interactions)

Decreased Requirements:

• Weight loss
• Aging
• Certain medications
• Improved malabsorption

5. Pharmacokinetics

Absorption

Oral Bioavailability

Levothyroxine (T4) Component:

• Absorption ranges 48-79% of administered dose
• Fasting increases absorption
• Similar to synthetic levothyroxine

Liothyronine (T3) Component:

• Almost completely absorbed
• ~95% absorbed within 4 hours
• More rapid and complete than T4

Food and Drug Effects on Absorption

Decrease Absorption:

• Food (especially fiber)
• Calcium supplements
• Iron supplements
• Aluminum-containing antacids
• Proton pump inhibitors
• Coffee (even without food)

Timing Recommendations:

• Empty stomach administration optimal
• Separate from interfering substances by 4+ hours

Distribution

Protein Binding

Both T4 and T3 are highly protein-bound in plasma:

Binding Proteins:

Free Hormone:

• Only free (unbound) hormone is biologically active
• T4: ~0.03% free
• T3: ~0.3% free

Volume of Distribution

• T4: Distributes primarily in intravascular space initially
• T3: More widely distributed to tissues
• Both accumulate in thyroid hormone-responsive tissues

Metabolism

T4 to T3 Conversion

Deiodinase Enzymes:

• D1 (liver, kidney): Produces T3 from T4
• D2 (brain, pituitary, brown fat): Local T3 production
• D3: Inactivates T4 and T3

Peripheral Conversion:

• ~80% of circulating T3 from T4 conversion
• ~20% from thyroid gland directly
• DTE bypasses some need for conversion

Metabolic Pathways

Primary:

• Deiodination (removal of iodine atoms)
• T4 → T3 (activation)
• T4 → rT3 (inactivation)
• T3 → T2 (inactivation)

Secondary:

• Conjugation (glucuronidation, sulfation)
• Hepatic metabolism
• Biliary excretion

Elimination

Half-Lives

Clinical Significance of T3 Half-Life:

• Peak T3 levels occur 2-4 hours post-dose
• Trough levels occur before next dose
• Greater T3 fluctuation than with T4 alone
• Rationale for divided dosing by some practitioners

Excretion

Primary Routes:

• Fecal: Major route for conjugated metabolites
• Urinary: Minor route
• Biliary: Conjugates excreted in bile

Steady-State Considerations

Time to Steady State

T4 Component:

• ~4-6 weeks to reach steady state
• Long half-life means gradual accumulation
• Lab testing should wait until steady state

T3 Component:

• Reaches steady state more rapidly (~1 week)
• Daily fluctuations continue at steady state
• Timing of blood draw affects measured T3

Laboratory Timing

Optimal Blood Draw:

• Morning, before taking daily dose
• Reflects trough T3 levels
• T4 levels less affected by timing
• Consistent timing for serial measurements

Pharmacokinetic Variability

Batch-to-Batch Variation

Concern with DTE Products:

• FDA has noted potential inconsistency
• T4:T3 ratio may vary between batches
• Biological source inherently variable
• May require dose adjustments when changing lots

Inter-Individual Variability

Factors Affecting Pharmacokinetics:

• Age (elderly have altered kinetics)
• Body weight
• Renal function
• Hepatic function
• Pregnancy (marked changes)
• Concurrent medications
• Genetic factors (DIO2 polymorphisms)

Comparison to Synthetic Preparations

Armour Thyroid vs Levothyroxine PK

6. Side Effects and Adverse Reactions

Common Side Effects

Symptoms of Overtreatment (Thyrotoxicosis)

The most common adverse effects relate to excessive thyroid hormone:

Cardiovascular:

• Palpitations (reported in ~20% in some studies)
• Tachycardia
• Increased heart rate
• Arrhythmias
• Chest pain

Neuropsychiatric:

• Anxiety (reported by 12% in one study)
• Nervousness/irritability
• Insomnia
• Tremor
• Headache

Metabolic:

• Weight loss
• Heat intolerance
• Excessive sweating
• Increased appetite

Gastrointestinal:

• Diarrhea
• Nausea
• Abdominal cramps

Musculoskeletal:

• Muscle weakness
• Muscle cramps

Comparative Adverse Event Rates

Armour Thyroid vs Levothyroxine Study Data

From a retrospective study of 125 patients:

Interpretation:

• Armour Thyroid associated with higher adverse effect rate
• Palpitations more common with DTE
• Some patients feel better, others worse

Serious Adverse Events

Cardiac Arrhythmias

Atrial Fibrillation Risk:

• T3 excess increases atrial fibrillation risk
• Higher with DTE than levothyroxine alone
• Risk increases with age
• Particularly concerning in elderly

Mechanism:

• T3 shortens cardiac refractory period
• Direct effect on cardiac ion channels
• Creates proarrhythmic substrate

Clinical Cases: Published case report of "Armour Thyroid Rage" described severe psychiatric and cardiac effects from excessive DTE dosing.

Bone Loss

Osteoporosis Risk:

• Excessive thyroid hormone accelerates bone turnover
• Net bone loss with chronic overtreatment
• Increased fracture risk
• Greater concern with T3 than T4 alone

At-Risk Populations:

• Postmenopausal women
• Elderly patients
• Those with existing osteoporosis
• Long-term treatment

Angina and Myocardial Infarction

Cardiac Ischemia Risk:

• Thyroid hormone increases myocardial oxygen demand
• Can precipitate angina in coronary disease
• Risk of MI with rapid dose escalation
• Start low, go slow in cardiac patients

T3-Specific Effects

Exaggerated T3 Peak

Concern with DTE:

• Supraphysiologic T3 peaks after dosing
• Human thyroid doesn't produce bolus T3
• May contribute to symptoms and risks

Comparison:

Psychological Effects

T3 Effects on Mood:

• Can cause anxiety, irritability
• Some patients report improved well-being
• Individual responses vary widely
• Case reports of severe psychiatric symptoms

Allergic Reactions

Potential Allergens in DTE

Components that may cause reactions:

• Porcine (pig) proteins
• Thyroglobulin
• Other thyroid gland constituents
• Inactive ingredients

Manifestations:

• Urticaria (hives)
• Rash
• Angioedema (rare)
• Anaphylaxis (very rare)

Hair Effects

Hair Changes

• Temporary hair loss can occur during dose adjustments
• Usually resolves as dose stabilizes
• May occur with any thyroid preparation
• Not specific to DTE

Laboratory Abnormalities

TSH Patterns

With DTE:

• TSH may be more suppressed than expected
• T3 component strongly suppresses TSH
• Some practitioners accept lower TSH on DTE
• Doesn't necessarily indicate overtreatment

T3:T4 Ratio

• Ratio higher than with levothyroxine alone
• Expected finding with combined T4/T3 therapy
• Some interpret this as more "balanced"

7. Drug Interactions

Absorption Interactions

Substances That Decrease Thyroid Hormone Absorption

Calcium-Containing Products:

Iron-Containing Products:

Antacids and Acid Suppressants:

Other:

• Sucralfate: Significant absorption reduction
• Cholestyramine: Binds thyroid hormones
• Colestipol: Binds thyroid hormones
• Coffee (even decaf): Reduces absorption
• Sevelamer: Reduces absorption
• Fiber supplements: Reduce absorption

Metabolism Interactions

Drugs Affecting Thyroid Hormone Metabolism

Enzyme Inducers (Increase Metabolism):

Enzyme Inhibitors (Decrease Metabolism):

Protein Binding Interactions

Drugs Affecting Thyroid Hormone Binding

Increase TBG:

• Estrogens/oral contraceptives: May need higher dose
• Tamoxifen: May need dose adjustment
• Pregnancy: Significant dose increase needed

Decrease TBG:

• Androgens: May need lower dose
• Anabolic steroids: May need lower dose
• Glucocorticoids (high dose): May need lower dose

Displace from Binding Proteins:

• Salicylates (high dose): Transient free T4 increase
• Furosemide (IV, high dose): Transient free T4 increase
• NSAIDs: Variable effects

Pharmacodynamic Interactions

Enhanced Effects

Sympathomimetics:

• Epinephrine, norepinephrine
• Increased cardiovascular effects
• Use with caution

Anticoagulants (Warfarin):

• Thyroid hormone increases warfarin effect
• INR may increase with DTE initiation
• Monitor INR closely when starting/adjusting

Digoxin:

• Thyroid hormone may decrease digoxin levels
• Hyperthyroid state decreases digoxin effect
• May need digoxin dose adjustment

Reduced Effects

Diabetes Medications:

• Thyroid hormone increases blood glucose
• May need insulin/oral agent adjustment
• Monitor glucose closely

Beta Blockers:

• Reduce some symptoms of thyrotoxicosis
• May need dose adjustment with thyroid changes

Antidepressant Interactions

Tricyclic Antidepressants (TCAs)

Potential Enhancement:

• Thyroid hormone may enhance TCA effects
• Risk of cardiac toxicity
• Use combination with caution
• Monitor cardiac status

SSRIs/SNRIs

• Generally no significant interaction
• Monitor for serotonin-related effects

Specific Drug Considerations

Oral Contraceptives

Interaction:

• Estrogens increase TBG
• More thyroid hormone bound
• May need DTE dose increase
• Monitor TSH

Ketamine

Important Interaction:

• Combination may cause hypertension
• Increased tachycardia risk
• Use with caution

Iodine-Containing Medications

Amiodarone:

• Contains large amounts of iodine
• Can cause hypo- or hyperthyroidism
• Complex interaction
• Requires close monitoring

Iodinated Contrast:

• May affect thyroid function
• Usually transient effects
• Monitor if receiving DTE

8. Contraindications

Absolute Contraindications

Uncorrected Thyrotoxicosis

Rationale:

• Adding exogenous thyroid hormone worsens hyperthyroidism
• Risk of thyroid storm
• All forms of hyperthyroidism must be controlled first

Includes:

• Graves' disease (untreated)
• Toxic multinodular goiter
• Toxic adenoma
• Thyroiditis-related hyperthyroidism
• Iatrogenic hyperthyroidism

Uncorrected Adrenal Insufficiency

CRITICAL CONTRAINDICATION

Rationale:

• Thyroid hormone increases cortisol clearance
• Increases metabolic rate and cortisol demand
• Can precipitate acute adrenal crisis
• Must correct with glucocorticoids BEFORE starting thyroid

Management:

1. Diagnose adrenal insufficiency
2. Initiate appropriate glucocorticoid replacement
3. Stabilize on steroid replacement
4. Then cautiously initiate thyroid hormone

Hypersensitivity

To DTE or Components:

• Porcine (pig) protein allergy
• Prior reaction to DTE products
• Allergy to inactive ingredients

Alternative:

• Synthetic levothyroxine (not porcine-derived)
• Liothyronine (synthetic)

Acute Myocardial Infarction

Rationale:

• Thyroid hormone increases myocardial oxygen demand
• Can extend infarct size
• Wait until cardiac status stabilized

Exception:

• May be used with caution in patients with chronic thyroid replacement who suffer MI
• Hold or reduce dose temporarily

Relative Contraindications/Precautions

Cardiovascular Disease

Conditions Requiring Caution:

• Coronary artery disease
• Angina pectoris
• Heart failure
• Arrhythmias (especially atrial fibrillation)
• Hypertension

Management:

• Start with very low doses (15 mg)
• Very gradual titration
• Close cardiac monitoring
• May need lower target dose
• Consider cardiology consultation

Elderly Patients

Increased Risk:

• Greater cardiac sensitivity
• Higher arrhythmia risk
• Possible occult cardiac disease
• Bone loss concerns

Approach:

• Very cautious initiation
• Lower starting doses
• Slower titration
• May not need full replacement

Diabetes Mellitus

Considerations:

• Thyroid hormone can increase blood glucose
• May need diabetes medication adjustment
• Monitor glucose closely during initiation

Autonomic Disorders

Concern:

• May exacerbate symptoms
• Particularly those affecting heart rate

Porcine Product Considerations

Religious/Dietary Restrictions

Patients Who Avoid Pork:

• Jewish patients following kosher laws
• Muslim patients following halal requirements
• Some Hindu dietary practices
• Vegetarian/vegan patients

Alternatives:

• Synthetic levothyroxine
• Synthetic liothyronine
• Bovine-derived products (limited availability)

Allergy Concerns

Cross-Reactivity:

• Patients with pork allergy should avoid
• Prior DTE reaction contraindicates re-challenge
• May use synthetic alternatives

Situations Requiring Careful Assessment

Pregnancy

• DTE can be used during pregnancy
• Dose requirements typically increase
• Close monitoring essential
• Some prefer synthetic for consistency

Breastfeeding

• Thyroid hormones enter breast milk minimally
• Generally safe during breastfeeding
• Adequate maternal thyroid function important

Mental Health Conditions

• Thyroid dysfunction affects mood
• Both hypo- and hyperthyroidism worsen psychiatric symptoms
• Careful dosing important in psychiatric patients

9. Special Populations

Pediatric Patients

Not Typical Use

• Pediatric hypothyroidism usually treated with levothyroxine
• DTE not standard of care in children
• Dosing information limited
• If used, requires specialized pediatric endocrinology guidance

Geriatric Patients

Increased Sensitivity

Concerns in Elderly:

• Greater cardiac sensitivity to thyroid hormones
• Higher atrial fibrillation risk
• More likely to have occult cardiac disease
• Bone loss concerns more significant

Dosing Modifications:

• Initial dose: 15 mg (1/4 grain) or less
• Very slow titration: Every 6-8 weeks
• Lower target doses may be appropriate
• TSH targets may be slightly higher

Monitoring:

• More frequent cardiac monitoring
• ECG at baseline and during titration
• Consider bone density assessment
• Watch for subtle overtreatment signs

Cardiac Patients

Extreme Caution Required

Initiation in Coronary Disease:

• Start with lowest possible dose (15 mg or 7.5 mg)
• Very slow titration over months
• Monitor for angina or arrhythmia
• May never achieve full replacement
• Cardiology involvement recommended

Post-MI or Unstable Angina:

• Generally hold thyroid hormone temporarily
• Restart at reduced doses once stable
• Individualized approach required

Pregnancy

Increased Requirements

Typical Changes:

• Thyroid hormone needs increase 30-50% during pregnancy
• Increase begins early (first trimester)
• Most pronounced in second and third trimesters
• Returns to pre-pregnancy dose postpartum

Monitoring:

• TSH every 4-6 weeks during pregnancy
• More frequent in first trimester
• Free T4 monitoring also important
• Immediate dose adjustment if needed

DTE vs Levothyroxine in Pregnancy:

• Synthetic levothyroxine often preferred
• More consistent dosing
• Easier to adjust precisely
• DTE acceptable if previously established

Breastfeeding

Generally Safe

• Minimal thyroid hormone transfer to breast milk
• Adequate maternal thyroid function supports lactation
• No contraindication to breastfeeding on DTE
• Continue appropriate replacement

Renal Impairment

Limited Data

• No specific dose adjustments established
• Thyroid hormones not primarily renally excreted
• Protein binding may be affected in severe renal disease
• Monitor and adjust based on labs and symptoms

Hepatic Impairment

Metabolic Considerations

• Liver involved in T4 to T3 conversion
• Severe hepatic disease may affect metabolism
• TBG levels may be affected
• Monitor closely in cirrhosis

Dose Adjustments:

• No specific recommendations
• Start low and titrate carefully
• Monitor thyroid function tests closely
• Watch for signs of over/undertreatment

Patients with Conversion Defects

DIO2 Polymorphisms

Consideration:

• Some patients have genetic variants affecting T4 to T3 conversion
• May benefit from combined T4/T3 therapy
• DTE provides this combination
• Research ongoing on genetic selection for DTE

Patients Switching from Levothyroxine

Transition Considerations

Why Patients Switch:

• Persistent symptoms despite normal TSH
• Preference for "natural" product
• Perceived improvement on T3-containing therapy

Transition Protocol:

1. Calculate equivalent DTE dose from conversion table
2. May start at 75% of calculated dose
3. Monitor TSH, free T4, free T3 after 4-6 weeks
4. Adjust based on symptoms and labs
5. Patient education about different response patterns

10. Monitoring Parameters

Pre-Treatment Evaluation

Required Assessments

Laboratory Testing:

• TSH (baseline)
• Free T4
• Free T3 (or total T3)
• Consider thyroid antibodies (TPO, TgAb)

If Not Previously Done:

• CBC
• Basic metabolic panel
• Lipid panel (hypothyroidism affects lipids)

Cardiac Assessment (if indicated):

• ECG (especially in elderly or cardiac patients)
• Consider baseline cardiac evaluation in at-risk patients

Bone Health (in at-risk patients):

• Consider bone density (DXA) if risk factors
• Baseline if postmenopausal woman

Ongoing Laboratory Monitoring

TSH Monitoring Schedule

Optimal Timing of Blood Draw

For DTE Patients:

• Draw blood BEFORE morning dose
• Reflects trough T3 levels
• Consistent timing essential
• Note timing on lab order

Why Timing Matters:

• T3 peaks 2-4 hours after dose
• Drawing after dose shows higher T3
• Could lead to inappropriate dose reduction

Target Levels

Typical Goals (General Guidance)

Special Considerations on DTE:

• TSH may be more suppressed due to T3 content
• Some practitioners accept lower TSH on DTE
• Clinical symptoms important in dose adjustment
• Not purely lab-driven decision

Clinical Monitoring

Symptom Assessment

Hypothyroid Symptoms to Monitor:

• Fatigue/energy level
• Cold intolerance
• Weight changes
• Cognitive function
• Mood/depression
• Constipation
• Hair and skin quality

Overtreatment Symptoms to Avoid:

• Palpitations
• Anxiety/irritability
• Tremor
• Heat intolerance
• Weight loss
• Insomnia
• Diarrhea

Heart Rate and Blood Pressure

• Monitor at each visit
• Resting heart rate >90-100 suggests overtreatment
• Widened pulse pressure may indicate excess

Cardiac Monitoring

Indications for ECG

• Elderly patients (baseline and periodically)
• Known cardiac disease
• Palpitations or arrhythmia symptoms
• Significant dose increases

Atrial Fibrillation Screening

• Pulse check at each visit
• Low threshold for ECG if irregular pulse
• Patient education on symptoms

Bone Health Monitoring

DXA Scanning

Consider in:

• Postmenopausal women on long-term therapy
• Patients with osteoporosis risk factors
• If TSH chronically suppressed
• Elderly patients

Frequency:

• Baseline if indicated
• Every 2 years if on long-term therapy
• More frequently if abnormal

Weight Monitoring

Track Body Weight

• Unexplained weight loss may indicate overtreatment
• Weight gain may indicate undertreatment
• Part of overall clinical assessment

Special Monitoring Situations

Pregnancy Monitoring

• TSH every 4-6 weeks
• Adjust dose promptly for abnormal TSH
• Monitor for adequate free T4
• Postpartum dose typically decreases

Post-Dose Adjustment Monitoring

• Allow 4-6 weeks to reach steady state
• Measure TSH (and T4/T3) at nadir (before AM dose)
• Clinical assessment for symptoms

Switching from Levothyroxine

• More frequent monitoring during transition
• TSH, free T4, free T3 at 4-6 weeks
• Symptom diary may be helpful
• May need multiple adjustments

11. Cost and Availability

Current Market Status

United States - Uncertain Future

Regulatory Situation (August 2025):

• FDA sent warning letters to all DTE manufacturers
• Products classified as unapproved biological products
• Manufacturers must obtain BLA approval for continued marketing
• Transition period granted (timeline unclear)
• Future availability uncertain

Market Presence:

• Still available as of late 2025
• ~1.5 million US patients currently use DTE products
• Represents ~6% of thyroid hormone prescriptions
• 94% of patients use FDA-approved levothyroxine

Available Products

Brand Name DTE Products

Pricing

Approximate US Retail Prices

Armour Thyroid:

Cost Comparison:

Insurance Coverage

Variable Coverage

Considerations:

• Some insurers cover DTE products
• Prior authorization may be required
• May require documentation of levothyroxine trial
• Coverage policies vary significantly

Trends:

• Coverage increasingly questioned
• FDA unapproved status may affect future coverage
• Some patients pay out-of-pocket

Generic Alternatives

DTE Generic Products

• Generic thyroid tablets available
• Same composition as branded products
• Lower cost option
• Same regulatory concerns apply

Supply Issues

Historical Supply Problems

• DTE products have experienced periodic shortages
• Manufacturing challenges with biological source
• Consistency issues have occurred
• Some products recalled for potency issues

NP Thyroid Recall (2020):

• Acella recalled NP Thyroid
• Subpotent tablets identified
• Illustrates manufacturing challenges

Future Availability Concerns

Regulatory Pathway

For Continued Availability:

1. Manufacturers must file BLA applications
2. BLA process typically takes 3-10 years
3. Significant investment required
4. Not all manufacturers may pursue approval

AbbVie Statement:

• Reportedly preparing preliminary BLA steps
• No confirmed timeline
• Armour Thyroid most likely to pursue approval

Patient Preparation

Recommended Actions:

• Discuss alternatives with healthcare provider
• Consider transition planning
• Obtain adequate supply while available
• Understand levothyroxine alternatives

International Availability

Limited Global Market

• DTE products primarily US market
• Most countries use synthetic thyroid hormones
• Some international pharmacies may supply
• Importation regulations apply

12. Clinical Evidence Summary

Comparative Effectiveness Studies

Armour Thyroid vs Levothyroxine

Key Study: Tale of Two Therapies

Design:

• Retrospective analysis of 125 patients
• Compared outcomes on Armour Thyroid vs levothyroxine

Key Findings:

Interpretation:

• More adverse effects with Armour Thyroid
• Some patients prefer and feel better on DTE
• Individual variation significant

Historic NIH-Sponsored Trial (2013)

Design:

• Double-blind crossover trial
• 70 hypothyroid patients
• Compared DTE vs levothyroxine

Findings:

• No significant difference in hypothyroid symptoms
• No significant difference in quality of life
• DTE resulted in higher T3 levels
• DTE resulted in lower TSH levels
• 49% of patients preferred DTE (vs 19% levothyroxine)

Limitations:

• Short treatment periods
• Relatively small sample size
• Crossover design limitations

T4/T3 Combination Therapy Studies

Meta-Analyses

2006 Meta-Analysis:

• Combined 11 randomized trials
• Compared T4/T3 combination vs T4 alone
• No significant benefit for combination therapy
• No significant difference in mood or cognition

2012 European Thyroid Association Review:

• Reviewed evidence for combination therapy
• Concluded insufficient evidence for routine use
• Suggested potential benefit in subset of patients

Long-Term Safety Data

Limitations

Evidence Gaps:

• No large, long-term randomized trials of DTE
• Most evidence from observational studies
• Comparative long-term safety data limited
• Cardiac and bone outcomes insufficiently studied

Emerging Research

JCEM 2025 Study

Key Finding:

• Analysis published June 2025
• Compared DTE vs levothyroxine long-term outcomes
• Suggested levothyroxine-only patients may have higher dementia and mortality risk

Interpretation:

• Preliminary observational data
• Requires confirmation in controlled trials
• Mechanism unclear
• Does not establish causation

Professional Society Positions

American Thyroid Association (ATA)

2014 Guidelines Position:

• Levothyroxine monotherapy is treatment of choice
• Insufficient evidence to recommend DTE
• Notes lack of long-term safety data for DTE
• Suggests some patients may prefer DTE

Endocrine Society

Position:

• Similar to ATA
• Recommends levothyroxine as first-line
• Notes individual patient responses vary
• Does not recommend against DTE use

Patient Preference Studies

Survey Data

Consistent Finding:

• Significant subset of patients prefer DTE
• Report improved energy, mood, cognition
• Subjective improvement despite similar objective measures
• Preference not explained by measured outcomes

Possible Explanations:

• Placebo effect
• T3 effects not captured by standard measures
• Individual metabolic differences
• Patient expectations

13. Comparison with Alternatives

Armour Thyroid vs Levothyroxine (Synthroid, Generic)

Side-by-Side Comparison

When Each May Be Preferred

Armour Thyroid May Be Preferred:

• Persistent symptoms on levothyroxine
• Patient preference for "natural" product
• Suspected T4 to T3 conversion issues
• Prior positive experience with DTE

Levothyroxine Preferred:

• First-line therapy
• Consistent dosing needed
• Cardiac patients (lower T3 peaks)
• Pregnancy (easier adjustment)
• Religious restrictions on pork
• Assured long-term availability

Armour Thyroid vs Liothyronine (Cytomel)

Comparison

Armour Thyroid vs Combination T4/T3 Therapy

Synthetic Combination Option

Some practitioners prescribe:

• Levothyroxine (T4) + Liothyronine (T3)
• Allows independent dose adjustment
• More precise T4:T3 ratio control
• Both components FDA approved

Comparison:

Other DTE Products

Armour Thyroid vs NP Thyroid

Armour Thyroid vs Nature-Throid/WP Thyroid

Unique Positioning of Armour Thyroid

Advantages

1. Contains both T4 and T3 hormones
2. Longest history of clinical use
3. Single-pill convenience
4. Lower cost than synthetic combinations
5. Preferred by some patients

Disadvantages

1. Not FDA approved
2. Uncertain future availability
3. Inconsistent batch-to-batch
4. Higher T3 than physiologic ratio
5. Cardiac/bone safety concerns
6. Porcine source (religious/dietary issues)

14. Storage and Handling

Storage Requirements

Temperature

Recommended Storage:

• Store at controlled room temperature: 15-30°C (59-86°F)
• Protect from excessive heat
• Avoid storage above 30°C (86°F)
• Do not freeze

Light Protection

• Store in original container
• Protect from excessive light
• Container should remain closed when not in use

Humidity

• Protect from moisture
• Keep container tightly closed
• Avoid bathroom storage
• Desiccant may be included in packaging

Handling Precautions

General Handling

• No special handling required
• Standard pharmaceutical precautions apply
• Keep out of reach of children
• Avoid crushing tablets (may affect dose accuracy)

Healthcare Worker Considerations

• No special precautions for handling intact tablets
• Standard universal precautions
• Not considered hazardous

Stability Information

Shelf Life

• Typically 2-3 years from manufacture
• Check expiration date on label
• Do not use after expiration

Opened Container

• Use within labeled expiration
• Keep container tightly closed
• Replace cap after each use
• Note any changes in appearance

Signs of Degradation

Visual Inspection

• Tablets should maintain consistent appearance
• Discoloration may indicate degradation
• Crumbling or excessive powder concerning
• Unusual odor warrants replacement

Potency Concerns

• Thyroid hormones can degrade over time
• Improper storage accelerates degradation
• May lose potency before visible changes

Disposal

Proper Disposal Methods

Recommended:

• Drug take-back programs
• Return to pharmacy for disposal
• Follow local hazardous waste guidelines

If Take-Back Not Available:

• Mix with undesirable substance (coffee grounds, dirt)
• Place in sealed container
• Dispose in household trash
• Do not flush

Travel Considerations

Traveling with DTE

• Keep in original labeled container
• Carry adequate supply
• Protect from temperature extremes
• Carry in carry-on luggage (airline travel)

International Travel

• Carry prescription documentation
• Check destination country regulations
• May need letter from physician
• Supply for duration plus extra

15. Goal Archetype Integration

Applicable Goal Archetypes

Armour Thyroid (desiccated thyroid extract) is relevant for patients pursuing optimization in the following goal archetypes:

Primary Archetypes

Metabolic Optimization / Weight Management

• Thyroid hormones directly regulate basal metabolic rate
• Combined T4+T3 may provide more complete metabolic support
• DTE addresses potential conversion defects affecting metabolism
• Weight-resistant hypothyroid patients may benefit from T3 component

Energy & Fatigue Resolution

• Fatigue is cardinal symptom of hypothyroidism
• Some patients report superior energy on DTE vs T4 monotherapy
• T3 component provides more immediate cellular energy support
• Brain and muscle tissue particularly responsive to T3

Cognitive Enhancement / Brain Fog Reduction

• Thyroid hormones critical for cognitive function
• T3 crosses blood-brain barrier more readily than T4
• Local brain deiodinase (D2) converts T4 to T3
• Some patients with DIO2 polymorphisms may benefit from direct T3

Secondary Archetypes

Mood & Mental Health Support

• Hypothyroidism associated with depression and anxiety
• Thyroid optimization adjunctive to psychiatric treatment
• T3 augmentation studied in treatment-resistant depression
• Individual response to T3 varies significantly

Anti-Aging / Longevity

• Thyroid function naturally declines with age
• Optimal thyroid status associated with metabolic health
• Caution: Over-replacement accelerates aging markers (bone loss, cardiac strain)
• 2025 JCEM study suggested potential longevity benefits (requires confirmation)

Desiccated Thyroid vs Synthetic Combination Strategies

DTE (Armour Thyroid, NP Thyroid)

Composition:

• Fixed T4:T3 ratio of approximately 4:1
• Per grain (60 mg): 38 mcg T4 + 9 mcg T3
• Additional components: T2, T1, thyroglobulin

Best Suited For:

• Patients preferring "natural" or animal-derived products
• Those wanting single-pill simplicity
• Patients with persistent symptoms on T4 alone who prefer fixed-ratio
• Cost-conscious patients (lower than synthetic combination)

Limitations:

• Cannot adjust T4:T3 ratio independently
• Higher T3 relative to human physiology (4:1 vs 14:1 natural)
• Batch-to-batch variability potential
• Not FDA approved

Synthetic T4 + T3 Combination

Composition:

• Levothyroxine (T4) + Liothyronine (T3)
• Ratio adjustable based on patient needs
• Common ratios: 10:1 to 20:1 (more physiologic than DTE)

Best Suited For:

• Patients needing precise dose titration
• Those with cardiac concerns (lower T3 peaks achievable)
• Patients requiring very specific T4:T3 ratios
• Situations requiring independent adjustment of either hormone

Protocol Example (Synthetic Combination):

Goal-Specific Dosing Considerations

Metabolic Optimization Goals

• May tolerate slightly higher T3 exposure
• Monitor for overtreatment symptoms
• Weight loss plateau may indicate optimal dose reached
• Avoid TSH suppression below 0.1 mIU/L long-term

Cognitive/Energy Goals

• Some practitioners target upper-normal free T3
• Individual response guides dosing
• T3 timing may affect cognitive benefits (morning vs split dosing)
• Allow 6-8 weeks to assess cognitive response

16. Age-Stratified Dosing

Dosing by Age Group

Adults 18-50 Years (Standard Adult Dosing)

Initiation:

• Starting dose: 30 mg (1/2 grain) daily
• Healthy patients may tolerate 60 mg initial dose
• Titrate by 15-30 mg every 2-4 weeks

Maintenance:

• Typical range: 60-120 mg (1-2 grains) daily
• Some require 180-300 mg for full replacement
• Target TSH: 0.5-2.0 mIU/L for most patients

Monitoring Frequency:

• Labs 4-6 weeks after initiation
• After each dose change: wait 4-6 weeks
• Stable dose: every 6-12 months

Adults 51-65 Years (Transitional Caution)

Initiation:

• Starting dose: 15-30 mg (1/4 to 1/2 grain) daily
• More conservative in those with cardiovascular risk factors
• Titrate by 15 mg every 4-6 weeks

Maintenance:

• Typical range: 60-90 mg (1-1.5 grains) daily
• Higher doses may be appropriate but require careful monitoring
• Consider cardiac screening before dose increases

Additional Considerations:

• ECG at baseline recommended
• Bone density assessment for postmenopausal women
• More frequent symptom assessment during titration

Adults 65-75 Years (Geriatric Caution)

Initiation:

• Starting dose: 15 mg (1/4 grain) daily
• Very gradual titration essential
• Titrate by 15 mg every 6-8 weeks

Maintenance:

• Typical range: 30-60 mg (1/2 to 1 grain) daily
• Full replacement doses often not needed
• TSH targets may be slightly higher (1.0-3.0 mIU/L acceptable)

Increased Risks:

• Atrial fibrillation risk increases significantly
• Occult coronary artery disease more common
• Bone loss concerns more significant
• Cognitive effects of both hypo- and hyperthyroidism

Monitoring:

• Cardiac monitoring at baseline and during titration
• Consider Holter monitoring if palpitations
• Annual bone density in at-risk patients
• More frequent TSH monitoring (every 3-4 months initially)

Adults 75+ Years (Extreme Caution)

Initiation:

• Starting dose: 15 mg (1/4 grain) or lower
• Some clinicians start at 7.5 mg (1/8 grain equivalent)
• Titrate by 15 mg every 8-12 weeks

Maintenance:

• Typical range: 15-45 mg daily
• Full replacement rarely needed
• TSH targets: 2.0-4.0 mIU/L may be appropriate
• Subclinical hypothyroidism may not require treatment

Critical Considerations:

• Increased mortality risk with TSH suppression in elderly
• Atrial fibrillation risk highest in this age group
• Hip fracture risk significantly elevated with overtreatment
• Quality of life considerations vs biochemical optimization

Cardiology Involvement:

• Strongly recommended before initiating DTE
• Required if any cardiac history
• Lower threshold for stopping/reducing if symptoms arise

Pediatric Considerations

General Guidance:

• DTE not standard of care in pediatric hypothyroidism
• Levothyroxine preferred for children
• If DTE used, requires pediatric endocrinology supervision
• No established pediatric dosing guidelines

Starting Low in the Elderly: Clinical Rationale

Physiologic Changes with Aging:

1. Decreased cardiac reserve and increased arrhythmia susceptibility
2. Reduced hepatic metabolism of thyroid hormones
3. Altered protein binding affecting free hormone levels
4. Decreased renal clearance of metabolites
5. Increased sensitivity to sympathomimetic effects

Clinical Evidence:

• Studies show increased mortality with low TSH in elderly
• Atrial fibrillation risk increases 3-fold with subclinical hyperthyroidism
• Hip fracture risk increases with TSH < 0.5 mIU/L
• Cognitive benefits of optimization must be balanced against risks

17. Drug Interactions (Comprehensive)

Overview

Armour Thyroid drug interactions are fundamentally the same as levothyroxine and liothyronine interactions. The T3 component may have slightly more pronounced interactions due to its shorter half-life and direct receptor activity.

Absorption Interactions (Complete List)

Calcium-Containing Products

Iron Products

Acid-Modifying Agents

Bile Acid Sequestrants

Other Absorption Interactions

Metabolism Interactions

Enzyme Inducers (Increase Thyroid Hormone Clearance)

Deiodinase Inhibitors (Affect T4 to T3 Conversion)

Protein Binding Interactions

Drugs That Increase TBG

Drugs That Decrease TBG

Drugs That Displace from Binding Proteins

Pharmacodynamic Interactions

Anticoagulants

Cardiac Medications

Diabetes Medications

Antidepressants

Sympathomimetics

Critical Drug Interactions Summary

HIGH SEVERITY (Avoid or closely monitor):

• Warfarin: Monitor INR, adjust dose
• TCAs: Cardiac risk
• MAOIs: Contraindicated
• Cholestyramine/Colestipol: Separate by 4-6 hours
• Ketamine: Hypertensive crisis risk

MODERATE SEVERITY (Monitor and adjust):

• Calcium/Iron supplements: Separate by 4 hours
• PPIs: May need dose increase
• Enzyme inducers: May need significant dose increase
• Estrogens: May need dose increase
• Digoxin: May need digoxin increase

LOW SEVERITY (Be aware):

• Coffee: Wait 60 minutes
• Soy products: Consistent intake
• Beta-blockers: Useful, mask symptoms

18. Bloodwork Impact

Laboratory Tests Affected by Armour Thyroid

Primary Thyroid Function Tests

TSH (Thyroid-Stimulating Hormone)

Key Points:

• TSH may be more suppressed on DTE than levothyroxine alone
• T3 crosses blood-brain barrier and suppresses pituitary TSH release
• Lower TSH does not necessarily indicate overtreatment
• Some practitioners accept TSH 0.3-0.5 mIU/L on DTE

Free T4 (Thyroxine)

Key Points:

• Free T4 may be lower than expected on DTE
• Does not indicate undertreatment if symptoms controlled
• Compare to baseline, not just reference range
• Lower free T4 is offset by direct T3 supplementation

Free T3 (Triiodothyronine)

Critical Timing Considerations:

• Draw blood BEFORE morning dose
• T3 peaks 2-4 hours after dosing
• Post-dose draw falsely elevates free T3
• Consistent timing essential for serial comparison

Total T3

• May be used instead of free T3
• Less affected by binding protein changes
• Similar timing considerations apply

Reverse T3 (rT3)

• Not routinely measured
• May be elevated in chronic illness, stress
• DTE does not specifically address rT3
• Clinical utility debated

Thyroid Antibodies

Thyroid Peroxidase Antibodies (TPOAb)

• Not directly affected by DTE
• Useful for diagnosing Hashimoto's thyroiditis
• May decrease over time with treatment (some studies)
• Does not guide DTE dosing

Thyroglobulin Antibodies (TgAb)

• Not directly affected by DTE
• Important for thyroid cancer monitoring
• DTE contains thyroglobulin (consider for allergic patients)

Secondary Laboratory Effects

Lipid Panel

Clinical Relevance:

• Lipid improvement confirms adequate treatment
• Persistent dyslipidemia may indicate undertreatment
• Recheck lipids 3-6 months after stable dosing

Complete Blood Count (CBC)

Metabolic Panel

Other Laboratory Effects

Optimal Laboratory Monitoring Panel

Initial Evaluation

• TSH
• Free T4
• Free T3 (or Total T3)
• TPO antibodies (if not previously done)
• CBC
• CMP
• Lipid panel

Routine Monitoring (Every 6-12 months when stable)

• TSH
• Free T4
• Free T3

Annual Comprehensive Panel

• TSH, Free T4, Free T3
• CBC
• CMP
• Lipid panel

Laboratory Goals on DTE

Common Laboratory Pitfalls

Pitfall 1: Drawing labs post-dose

• Free T3 will be falsely elevated
• May lead to inappropriate dose reduction
• Always draw BEFORE morning dose

Pitfall 2: Targeting same TSH as T4 monotherapy

• TSH naturally lower on DTE
• Over-interpreting low TSH as overtreatment
• Clinical symptoms should guide dosing

Pitfall 3: Expecting high-normal free T4

• Free T4 typically lower on DTE
• T3 component provides direct hormone
• Low-normal free T4 is expected and acceptable

Pitfall 4: Not considering binding protein changes

• Estrogen therapy increases TBG
• May affect interpretation
• Free hormone levels more reliable than total

19. Protocol Integration

Armour Thyroid vs Synthetic Levothyroxine

When to Consider DTE Over Levothyroxine

Strong Indications:

1. Persistent symptoms despite optimal TSH on levothyroxine
2. Patient-reported improved quality of life on prior DTE
3. Suspected T4 to T3 conversion defects (DIO2 polymorphisms)
4. Patient strongly prefers "natural" product after informed consent

Moderate Indications:

1. Treatment-resistant depression (T3 augmentation consideration)
2. Persistent fatigue with normal thyroid labs on T4
3. Symptomatic despite multiple levothyroxine brands/adjustments

Weak Indications (Insufficient Evidence):

1. Routine hypothyroidism without prior T4 trial
2. Subclinical hypothyroidism
3. General wellness optimization in euthyroid patients

When to Prefer Levothyroxine Over DTE

Strong Indications:

1. First-line treatment for newly diagnosed hypothyroidism
2. Cardiac disease (atrial fibrillation history, CAD)
3. Elderly patients (>65 years)
4. Pregnancy (easier precise adjustment)
5. Osteoporosis or high fracture risk
6. Religious/dietary restrictions on pork products
7. Need for long-term availability certainty

Moderate Indications:

1. Patients tolerating and responding well to T4
2. Need for very precise dosing
3. Insurance coverage concerns
4. Anxiety/panic disorder (T3 may exacerbate)

Consistency Concerns with DTE

Batch-to-Batch Variability

The Problem:

• Biological source (porcine thyroid) inherently variable
• FDA has noted potential inconsistency between batches
• T4:T3 ratio may vary slightly between lots
• Manufacturing standardization challenges

Clinical Implications:

• Symptoms may fluctuate when changing to new lot
• TSH may vary without dose change
• Some patients report needing dose adjustments with new supply
• More problematic for patients sensitive to small changes

Mitigation Strategies:

1. Use same brand consistently (don't switch between Armour, NP Thyroid, etc.)
2. Request same lot number when possible
3. Monitor symptoms when starting new supply
4. Consider synthetic combination for most consistency-sensitive patients

Brand Switching Concerns

Protocol for Switching to DTE

From Levothyroxine to Armour Thyroid

Step 1: Evaluation

• Confirm reason for switch is appropriate
• Document baseline TSH, free T4, free T3
• Assess cardiac risk factors
• Discuss regulatory status and future availability

Step 2: Conversion

• Use conversion table (approximate):
  • 100 mcg levothyroxine = 60 mg (1 grain) Armour
  • Consider starting at 75% of calculated dose
• Example: 150 mcg T4 → Start with 60-90 mg Armour

Step 3: Initiation

• Discontinue levothyroxine
• Start Armour Thyroid the next day
• Take on empty stomach, AM dosing

Step 4: Monitoring

• Check TSH, free T4, free T3 at 4-6 weeks
• Assess symptoms at each visit
• Adjust dose in 15-30 mg increments
• Recheck labs 4-6 weeks after each change

Step 5: Maintenance

• Once stable, monitor every 6-12 months
• Educate patient on overtreatment symptoms
• Discuss contingency if DTE becomes unavailable

Protocol for Switching from DTE

From Armour Thyroid to Levothyroxine

Indications for Switch:

• Development of cardiac issues
• DTE availability concerns
• Patient preference
• Intolerance to DTE
• Pregnancy planning

Step 1: Conversion

• 60 mg (1 grain) Armour = approximately 100 mcg levothyroxine
• May slightly under-convert initially

Step 2: T3 Consideration

• If patient benefited from T3 component:
  • Consider adding liothyronine 5-10 mcg daily
  • Divide liothyronine into 2-3 daily doses
• If switching due to T3 intolerance:
  • Convert to levothyroxine only

Step 3: Monitoring

• Check TSH, free T4, free T3 at 6-8 weeks
• Longer wait than DTE initiation (T4 half-life)
• Symptom assessment important

Step 4: Adjustment

• Adjust levothyroxine by 12.5-25 mcg increments
• If on combination, adjust each independently
• Target TSH may be higher than on DTE

Integration with Other Protocols

DTE and HRT (Hormone Replacement Therapy)

Estrogen Interactions:

• Estrogen increases TBG
• May need DTE dose increase with HRT initiation
• Monitor TSH 6-8 weeks after starting HRT
• Typical increase: 10-25%

Testosterone Therapy:

• Androgens decrease TBG
• May need DTE dose decrease
• Monitor TSH with testosterone changes

DTE and Weight Management Protocols

Considerations:

• DTE supports metabolism but is not a weight loss drug
• Overtreatment for weight loss is dangerous
• Thyroid optimization is one component of metabolic health
• Do not target suppressed TSH for weight goals

Safe Integration:

• Optimize DTE dose for symptom relief, not weight loss
• Monitor TSH to avoid overtreatment
• Address weight through nutrition, exercise, other protocols
• Consider T3 timing (AM) for daytime metabolic support

DTE and Depression Treatment

T3 Augmentation Research:

• T3 studied as augmentation for treatment-resistant depression
• DTE provides T3 but in fixed ratio
• Psychiatry guidance recommended for this indication

Integration Points:

• Monitor for anxiety exacerbation (T3 effect)
• Coordinate with psychiatrist on antidepressant interactions
• TCA interactions require caution
• May improve energy and mood in hypothyroid depression

Future Availability Planning

Contingency Protocols

Given FDA regulatory action (August 2025), practices should have contingency plans:

Option 1: Synthetic Combination

• Levothyroxine + Liothyronine
• Requires multiple pills
• More precise ratio control
• Both FDA approved

Option 2: Levothyroxine Monotherapy

• Most patients do well on T4 alone
• Start with equivalent dose
• Reassess need for T3 after transition
• Lower risk profile

Option 3: Compounded T4/T3

• FDA guidance discourages compounding for DTE (biological product)
• Compounded synthetic T4/T3 may be option
• Quality and consistency concerns
• State pharmacy board regulations vary

Patient Communication:

• Inform patients of regulatory status
• Discuss alternatives proactively
• Develop transition plan before shortage
• Document patient preferences

20. References

Primary Literature

Clinical Studies

1. Hoang TD, Olsen CH, Mai VQ, et al. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98(5):1982-1990.

2. Celi FS, Zemskova M, Linderman JD, et al. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab. 2011;96(11):3466-3474.

3. Saravanan P, Chau WF, Roberts N, et al. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57(5):577-585.

4. Burch HB. Drug Effects on the Thyroid. N Engl J Med. 2019;381(8):749-761.

Pharmacology Studies

5. Bianco AC, Casula S. Thyroid hormone replacement therapy: three 'simple' questions, complex answers. Eur Thyroid J. 2012;1(2):88-98.

6. Wiersinga WM, Duntas L, Fadeyev V, et al. 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. Eur Thyroid J. 2012;1(2):55-71.

7. Samuels MH, Kolobova I, Niederhausen M, et al. Effects of Levothyroxine Replacement or Suppressive Therapy on Energy Expenditure and Body Composition. Thyroid. 2016;26(3):347-355.

Safety and Adverse Effects

8. Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95(1):186-193.

9. Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J. 2015;4(3):149-163.

10. Perros P, Basu A, Gait JC, et al. Armour Thyroid Rage: A Dangerous Mixture. Case Rep Endocrinol. 2018;2018:5765409.

Guidelines and Position Statements

11. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751.

12. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200-1235.

13. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.

Regulatory Documents

14. U.S. Food and Drug Administration. FDA's Actions to Address Unapproved Thyroid Medications. August 2025. https://www.fda.gov/drugs/enforcement-activities-fda/fdas-actions-address-unapproved-thyroid-medications

15. U.S. Food and Drug Administration. Animal-derived thyroid products notice to industry. August 2025.

16. DailyMed. Armour Thyroid - thyroid, porcine tablet. https://dailymed.nlm.nih.gov

Product Information

17. AbbVie Inc. Armour Thyroid (thyroid tablets, USP) Prescribing Information.

18. Acella Pharmaceuticals, LLC. NP Thyroid (Thyroid Tablets, USP) Prescribing Information.

Review Articles

19. Biondi B, Wartofsky L. Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab. 2012;97(7):2256-2271.

20. Wartofsky L. Combination L-T3 and L-T4 therapy for hypothyroidism. Curr Opin Endocrinol Diabetes Obes. 2013;20(5):460-466.

Online Resources

21. GoodRx. Armour Thyroid Dosage Guide. https://www.goodrx.com/armour-thyroid/dosage

22. Paloma Health. What's Happening With Natural Desiccated Thyroid Drugs? https://www.palomahealth.com/learn/natural-desiccated-thyroid-drugs

23. DrugBank. Armour Thyroid Drug Entry. https://go.drugbank.com

Document History

Document Completion: 2025-12-26 Last Updated: 2026-01-05 Status: PAPER 47 OF 76 COMPLETE Next Paper: #48 - Liotrix